drugset / Trial / NCT06420973
RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.
Timeline
- Start
- 2024-05-16
- Primary completion
- 2027-05-17
- Completion
- 2027-09-17
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bevacizumab | Monoclonal antibody | 7.5 mg/kg | Intravenous |
| Subject | Bevacizumab | Monoclonal antibody | 15 mg/kg | Intravenous |
| Subject | Carboplatin | Small molecule | 5 unknown | Intravenous |
| Subject | Disitamab Vedotin | Other / unclassified | 2 mg/kg | Intravenous |
| Subject | Disitamab Vedotin | Other / unclassified | 2.5 mg/kg | Intravenous |